Document is current
Any future updates will be listed below
-
Authors
Martínez-Gómez, María https://orcid.org/0009-0008-4176-1056
Barberá, Aurora https://orcid.org/0000-0002-6201-2643
Raurell, Imma https://orcid.org/0000-0003-4477-7367
Cusidó, M. Serra https://orcid.org/0009-0006-2861-5375
Parks, Sophia C.
Salcedo, M. Teresa
Augustin, Salvador
Ventura-Cots, Meritxell
Genescà, Joan https://orcid.org/0000-0002-0831-8422
Martell, María https://orcid.org/0000-0002-0935-0029
Pericàs, Juan M.
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 26 February 2026
First Online: 3 April 2026
Competing interests
: J.M.P. reports having received consulting fees from the MSD, Madrigal, Boehringer-Ingelheim, and Novo Nordisk. He has received speaking fees from Madrigal, Gilead, Intercept and Novo Nordisk and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN and Novo Nordisk. He received educational and research support from Madrigal, Boehringer-Ingelheim, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV and MSD. The other authors declare no competing interests.
